Phreesia, Inc. (NYSE:PHR – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $16.6471.
A number of analysts have weighed in on the stock. Canaccord Genuity Group cut their target price on shares of Phreesia from $22.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, May 28th. Barclays reiterated an “equal weight” rating and set a $10.00 price target (down from $24.00) on shares of Phreesia in a report on Thursday, May 14th. Citigroup reiterated a “market perform” rating on shares of Phreesia in a research note on Friday, May 29th. Truist Financial raised their price objective on Phreesia from $11.00 to $12.00 and gave the company a “hold” rating in a report on Thursday, May 28th. Finally, Stephens cut their price objective on Phreesia from $32.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday, March 31st.
Check Out Our Latest Report on Phreesia
Institutional Trading of Phreesia
Phreesia Stock Down 5.5%
Shares of NYSE PHR opened at $10.02 on Monday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.41. The company has a market cap of $619.03 million, a price-to-earnings ratio of 66.77 and a beta of 0.87. Phreesia has a 12 month low of $7.77 and a 12 month high of $32.76. The stock has a 50-day moving average price of $9.81 and a two-hundred day moving average price of $11.20.
Phreesia (NYSE:PHR – Get Free Report) last posted its earnings results on Wednesday, May 27th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $130.94 million during the quarter, compared to analysts’ expectations of $130.08 million. Phreesia had a net margin of 1.85% and a return on equity of 5.13%. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.07) earnings per share. As a group, analysts forecast that Phreesia will post 0.39 earnings per share for the current fiscal year.
About Phreesia
Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.
Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.
Featured Stories
- Five stocks we like better than Phreesia
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.
